We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Gilead Claims Combo HCV Drug Achieves SVR12 in All Genotypes
Gilead Claims Combo HCV Drug Achieves SVR12 in All Genotypes
California biopharmaceutical company Gilead is reporting the first single table regimen combining two drugs proved effective in treating all six genotypes of hepatitis C in four clinical trials.